Clinical Trials

Numerous clinical trials evaluate candesartan across Early Phase 1 through Phase 4 for a broad spectrum of cardiovascular, renal, and metabolic indications, including arterial hypertension, chronic heart failure, dilated cardiomyopathy, and chronic kidney disease. Supported by both pharmaceutical sponsors and academic medical centers, these investigations encompass completed, active, and withdrawn protocols ranging from early interventions to large-scale primary prevention studies. Additional research addresses bioequivalence and SARS-CoV infections.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07655440 NOT_YET_RECRUITING
Migraine Associated Vertigo; Tinnitus; Migraine; Vestibular Migraine
Stanford University
 2026-07 PHASE4
NCT05826912 ENROLLING_BY_INVITATION
Traumatic Brain Injury
University of California, San Francisco
 2024-08-01 PHASE2
NCT07687160 NOT_YET_RECRUITING
Hypertension
Ottawa Hospital Research Institute
 2026-09-01 PHASE4
NCT03770936 RECRUITING
Liver Fibroses
Sherief Abd-Elsalam
 2018-10-01 PHASE3
NCT05321875 RECRUITING
Cardiomyopathy, Dilated
Cristina Avendaño Solá
 2022-06-02 PHASE3
NCT03583866 ACTIVE_NOT_RECRUITING
Hypertension
Augusta University
 2018-05-21 EARLY_PHASE1
NCT06646354 ENROLLING_BY_INVITATION
Hypertension; Primary Hypercholesterolaemia
Hyundai Pharm
 2025-04-22 PHASE3
NCT05920005 COMPLETED
Hypertension
Hospital Israelita Albert Einstein
 2023-08-22 PHASE3
NCT05271448 UNKNOWN
Contrast-induced Nephropathy; Chronic Kidney Diseases; Ischemic Heart Disease
An-Najah National University
 2021-06-01
NCT04574713 COMPLETED
Migraine
St. Olavs Hospital
 2021-04-09 PHASE2
NCT05122182 TERMINATED
COVID-19; SARS-CoV2 Infection
University of Sydney
 2022-01-07 PHASE2
NCT04429633 UNKNOWN
Cardiotoxicity; Breast Cancer; Prevention; Adjuvant; Trastuzumab
Samsung Medical Center
 2019-07-19
NCT04430959 WITHDRAWN
Bipolar Disorder Depression
The University of Texas Health Science Center, Houston
 2020-10-01 EARLY_PHASE1
NCT05321875 Recruiting
Cardiomyopathy Dilated
Cristina Avendaño Solá|Puerta de Hierro University Hospital
 2022-06-02 Phase 3
NCT03640312 COMPLETED
Hypertension
Washington University School of Medicine
 2019-08-30 PHASE2
NCT04606563 TERMINATED
Covid19; SARS-CoV Infection
University of British Columbia
 2020-10-09 PHASE3
NCT04351724 UNKNOWN
COVID-19
Medical University of Vienna
 2020-04-16 PHASE2; PHASE3
NCT03688633 TERMINATED
Peripheral Neuropathy
University Hospital, Limoges
 2019-05-01 PHASE2
NCT03847506 COMPLETED
Hypertension, Hyperlipidemia
HK inno.N Corporation
 2018-07-05 PHASE4
NCT02646982 COMPLETED
Mild Cognitive Impairment
Emory University
 2016-06-30 PHASE2
NCT04521023 COMPLETED
Hypertension
Chong Kun Dang Pharmaceutical
 2017-09-20 PHASE4
NCT02047019 WITHDRAWN
Hypertension
Bayer
 2017-12-01 PHASE3
NCT04012307 COMPLETED
Bioequivalence
Pharmtechnology LLC
 2019-07-11 PHASE1
NCT04012307 Completed
Bioequivalence
Pharmtechnology LLC|Altasciences Company Inc.
 2019-07-11 Phase 1
NCT03231982 UNKNOWN
Hypertension
HK inno.N Corporation
 2017-04-17 PHASE4
NCT04245046 COMPLETED
Healthy Volunteers
Midas Pharma GmbH
 2019-01-18 PHASE1
NCT01984164 COMPLETED
Hypertension; Mild Cognitive Impairment
Emory University
 2014-08-20 PHASE2
NCT02969265 WITHDRAWN
Hypertension
Takeda
 2017-05-09 PHASE3
NCT02521233 WITHDRAWN
Essential Arterial Hypertension
EMS
 2016-11 PHASE3
NCT02521246 WITHDRAWN
Essential Arterial Hypertension
EMS
 2016-11 PHASE3
NCT02988362 COMPLETED
Hypertension
HanAll BioPharma Co., Ltd.
 2016-12-14 PHASE1
NCT03017950 Completed
Hypertension|Hyperlipidemias
Chong Kun Dang Pharmaceutical
 2016-12 Phase 1
NCT03460327 Recruiting
Obesity Morbid
Norwegian University of Science and Technology|St. Olavs Hospital|Volvat Medisinsk Senter Stokkan|Namsos Hospital|Alesund Hospital
 2016-11-02 --
NCT02332824 COMPLETED
Type 2 Diabetes Mellitus and Microalbuminuria
Takeda
 2014-10-16 PHASE2
NCT02770261 COMPLETED
Hypertension; Cholesterolemia
Alvogen Korea
 2015-12 PHASE3
NCT01938664 TERMINATED
Cocaine Dependence
Baylor College of Medicine
 2013-01 PHASE2
NCT01678794 COMPLETED
Cardiorenal Syndrome (CRS)
Mayo Clinic
 2012-02 PHASE1; PHASE2
NCT02709187 COMPLETED
Healthy
Alvogen Korea
 2016-03 PHASE1
NCT02609711 UNKNOWN
Healthy Male Subjects
Ahn-Gook Pharmaceuticals Co.,Ltd
 2015-11 PHASE1
NCT02651870 COMPLETED
Hypertension
Chong Kun Dang Pharmaceutical
 2015-04-22 PHASE3
NCT01827202 COMPLETED
Hypertension; Chronic Kidney Disease; Proteinuria
Medical University of Vienna
 2012-12 PHASE4
NCT02614352 UNKNOWN
Healthy Male Subjects
Ahn-Gook Pharmaceuticals Co.,Ltd
 PHASE1
NCT00468923 COMPLETED
Cardiovascular Disease; Stroke
Population Health Research Institute
 2007-05 PHASE4
NCT02944734 COMPLETED
Essential Hypertension
Shin Poong Pharmaceutical Co. Ltd.
 2014-09 PHASE2
NCT02368665 COMPLETED
Essential Hypertension
HK inno.N Corporation
 2014-12 PHASE3
NCT02368652 COMPLETED
Essential Hypertension
HK inno.N Corporation
 2014-12 PHASE3
NCT02548286 COMPLETED
Hypertension
Chong Kun Dang Pharmaceutical
 2015-08 PHASE1
NCT01629225 UNKNOWN
Essential Hypertension
Third Military Medical University
 2013-07 PHASE4
NCT02059616 UNKNOWN
Essential Hypertension
HK inno.N Corporation
 2014-02 PHASE2
NCT02707224 COMPLETED
Healthy
Alvogen Korea
 2015-01 PHASE1
NCT02801526 COMPLETED
Hypertension
Chong Kun Dang Pharmaceutical
 2015-04 PHASE1
NCT02811731 COMPLETED
Hypertension
Chong Kun Dang Pharmaceutical
 2015-04 PHASE1
NCT02206165 UNKNOWN
Essential Hypertension
Chong Kun Dang Pharmaceutical
 2014-03 PHASE2
NCT01794455 TERMINATED
Depression; Hypertension
Vanderbilt University
 2013-05 PHASE4
NCT02254447 COMPLETED
Cardiovascular Disease
GlaxoSmithKline
 2014-12-02 PHASE1
NCT01162902 UNKNOWN
Stable Angina
Seoul National University Hospital
 2013-09 PHASE4
NCT01434134 COMPLETED
Breast Cancer; Heart Failure
University Hospital, Akershus
 2011-09 PHASE2
NCT02186496 COMPLETED
Hypertension
Chong Kun Dang Pharmaceutical
 2014-07 PHASE1
NCT02173912 UNKNOWN
Healthy Volunteers
HK inno.N Corporation
 2014-06 PHASE1
NCT02064621 COMPLETED
Hypertension
Chong Kun Dang Pharmaceutical
 2014-06 PHASE1
NCT02064556 COMPLETED
Hypertension
Chong Kun Dang Pharmaceutical
 2014-05 PHASE1
NCT02094924 COMPLETED
Hypertension
GlaxoSmithKline
 2014-04-17 PHASE1
NCT01788358 COMPLETED
Hypertension
Bayer
 2013-02-14 PHASE3
NCT01766505 TERMINATED
Hypertension
Chong Kun Dang Pharmaceutical
 2012-06 PHASE4
NCT02079506 COMPLETED
Healthy
Alvogen Korea
 2014-02 PHASE1
NCT02006589 COMPLETED
Hypertension
GlaxoSmithKline
 2013-12-11 PHASE1
NCT02006602 COMPLETED
Hypertension
GlaxoSmithKline
 2013-12-13 PHASE1
NCT01976572 COMPLETED
Hyperphosphatemia; Chronic Kidney Disease
Tanabe Pharma Corporation
 2013-10 PHASE1
NCT00459771 COMPLETED
Breast Cancer
The Netherlands Cancer Institute
 2007-06 PHASE3
NCT01062451 COMPLETED
Methamphetamine Dependence; Methamphetamine Abuse; Substance Abuse
Baylor College of Medicine
 2009-05 PHASE1
NCT01926652 COMPLETED
Healthy
Shin Poong Pharmaceutical Co. Ltd.
 2013-07 PHASE1
NCT01806311 COMPLETED
Hypertension
HanAll BioPharma Co., Ltd.
 2012-12 PHASE1
NCT00863980 TERMINATED
Acute Myocardial Infarction; Angina Pectoris; Myocardial Ischemia; Acute Coronary Syndrome; Hypertension
Kyoto Prefectural University of Medicine
 2009-04
NCT01845272 UNKNOWN
Healthy
HK inno.N Corporation
 2013-04 PHASE1
NCT01734096 COMPLETED
Hypertension; Obesity; White Coat Hypertension; Resistant Hypertension
PD Dr. Grégoire Wuerzner
 2009-05 PHASE4
NCT02879721 COMPLETED
Barrett's Esophagus
Göteborg University
 2009-10 EARLY_PHASE1
NCT01611077 COMPLETED
Hypertension
Institut für Pharmakologie und Präventive Medizin
 2012-01 PHASE4
NCT00699452 UNKNOWN
Aortic Valve Stenosis
University of Helsinki
 2009-05 PHASE3
NCT01613209 COMPLETED
Hypertension
Institut für Pharmakologie und Präventive Medizin
 2011-12 PHASE3
NCT01116180 COMPLETED
Type 1 Diabetes; Hypoglycemia
Louise Faerch
 2010-04
NCT01303783 COMPLETED
Hypertension, Essential
Bayer
 2011-04 PHASE2
NCT00884663 COMPLETED
Migraine Without Aura; Migraine With Aura; Chronic Migraine
Norwegian University of Science and Technology
 2009-04 PHASE2; PHASE3
NCT00605072 COMPLETED
Cognitive Impairment; Hypertension; Aging
University of Southern California
 2008-01 PHASE2
NCT01350609 COMPLETED
Hypertension, Essential
Bayer
 2011-04 PHASE1
NCT00607672 COMPLETED
Coronary Artery Disease; Angiotensin Converting Enzyme; Angiotensin Receptor Blockers; Cardiopulmonary Bypass; Fibrinolysis; Inflammation
Vanderbilt University
 2006-08 PHASE4
NCT01135212 COMPLETED
Hypertension
Boryung Pharmaceutical Co., Ltd
 2010-04 PHASE3
NCT01227603 COMPLETED
Hypertension, Essential
Bayer
 2010-11 PHASE1
NCT01052272 COMPLETED
Diabetes
University of Alabama at Birmingham
 2005-07 PHASE2; PHASE3
NCT00120003 COMPLETED
Stroke
Ullevaal University Hospital
 2005-06 PHASE3
NCT03136666 COMPLETED
Clinical Pharmacology
Bayer
 2010-04-19 PHASE1
NCT01025843 COMPLETED
Hypertension
Merck Sharp & Dohme LLC
 2009-12-01 PHASE1
NCT01012479 COMPLETED
Hypertension
Takeda
 2009-10 PHASE4
NCT00400582 COMPLETED
Heart Failure
Montreal Heart Institute
 2006-11 PHASE4
NCT00319202 TERMINATED
Glucose Intolerance; Obesity
Fundación Cardiovascular de Colombia
 2006-06 PHASE4
NCT00679484 TERMINATED
Chronic Heart Failure; High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
 2008-06 PHASE3
NCT00690612 COMPLETED
Hypertension
AstraZeneca
 2007-09 PHASE3
NCT00867490 COMPLETED
Hypertension
Novartis
 2009-03 PHASE3
NCT00573430 COMPLETED
Non-diabetic Nephropathy With Hypertension
AstraZeneca
 2007-12 PHASE4
NCT00844324 COMPLETED
Hypertension
AstraZeneca
 2009-03 PHASE1
NCT00538486 COMPLETED
Hypertension; Obesity
Third Military Medical University
 2008-02 PHASE4
NCT00184587 COMPLETED
Cluster Headache
Norwegian University of Science and Technology
 2005-03 PHASE2
NCT00139386 COMPLETED
Hypertension; Coronary Artery Disease
Kumamoto University
 2005-10 PHASE4
NCT01444833 UNKNOWN
Hypertension
Slovak Academy of Sciences
 2008-10
NCT00621153 COMPLETED
Stage II Hypertension
AstraZeneca
 2008-02 PHASE4
NCT00294775 UNKNOWN
Aortic Valve Stenosis; Left Ventricular Hypertrophy; Atrial Fibrillation
Odense University Hospital
 2006-02 PHASE3
NCT00391846 COMPLETED
Heart Failure; Ventricular Dysfunction, Left
AstraZeneca
 2006-10 PHASE4
NCT00775840 COMPLETED
Heart Failure
Takeda
 2008-01 PHASE3
NCT00990639 COMPLETED
Alcoholic Liver Disease
Yonsei University
 2005-09 PHASE1; PHASE2
NCT00905333 COMPLETED
Healthy
AstraZeneca
 2008-10 PHASE1
NCT00775814 COMPLETED
Obesity; Hypertension
Takeda
 2006-10 PHASE4
NCT00244621 COMPLETED
Hypertension
AstraZeneca
 2004-11 PHASE3
NCT00843154 TERMINATED
Heart Failure
Takeda
 2005-12 PHASE3
NCT01289132 COMPLETED
Essential Hypertension
Takeda
 2007-07 PHASE2
NCT00348686 COMPLETED
Hypertension; Left Ventricular Hypertrophy
AstraZeneca
 2006-06 PHASE4
NCT00252733 COMPLETED
Type 1 Diabetes
AstraZeneca
 2001-06 PHASE3
NCT00644475 UNKNOWN
Essential Hypertension
University of Pavia
 2008-03 PHASE3
NCT00252720 COMPLETED
Type 1 Diabetes
AstraZeneca
 2001-08 PHASE3
NCT00252694 COMPLETED
Type 2 Diabetes
AstraZeneca
 2001-08 PHASE3
NCT00434967 COMPLETED
Hypertension
AstraZeneca
 2007-01 PHASE3
NCT00383929 COMPLETED
Hypertension
AstraZeneca
 2006-09 PHASE3
NCT00310778 COMPLETED
Healthy
Assistance Publique - Hôpitaux de Paris
 2006-03 PHASE1
NCT00360178 COMPLETED
Hypertension
Novartis
 2006-07 PHASE3
NCT00232882 COMPLETED
Hypertension
Institut de Recherches Cliniques de Montreal
 2003-12 PHASE4
NCT00282178 COMPLETED
Hypertension; Obesity
Umeå University
 2005-04 PHASE2
NCT00227318 COMPLETED
Hypertension
AstraZeneca
 1998-07 PHASE3
NCT00150631 UNKNOWN
Hypertension
Karin Skov
 2000-11 PHASE3
NCT00634309 COMPLETED
Congestive Heart Failure
AstraZeneca
 1999-06 PHASE3
NCT00634400 COMPLETED
Congestive Heart Failure
AstraZeneca
 1999-03 PHASE3
NCT00634712 COMPLETED
Congestive Heart Failure
AstraZeneca
 1999-06 PHASE3
NCT02261116 COMPLETED
Healthy
Boehringer Ingelheim
 2002-04 PHASE4
NCT00587470 COMPLETED
Mitral Regurgitation
Mayo Clinic
 1998-08 PHASE4
NCT00244634 COMPLETED
Pediatric Hypertension
AstraZeneca
 2003-09 PHASE3
NCT00244595 COMPLETED
Hypertension
AstraZeneca
 2003-09 PHASE3
NCT00360763 UNKNOWN
Hypertension
Huazhong University of Science and Technology
 PHASE4
NCT00541853 UNKNOWN
Kidney, Polycystic, Autosomal Dominant
Kyorin University
 2007-12 PHASE4
NCT00130975 COMPLETED
Atrial Fibrillation
Asker & Baerum Hospital
 2001-04 PHASE3
NCT00530595 COMPLETED
Cardiovascular Disease
Saitama Medical University
NCT00154050 COMPLETED
Arterial Occlusive Diseases
Technische Universität Dresden
 2004-05
NCT00320970 COMPLETED
Diabetic Nephropathy; Hypertension
Providence Health & Services
 2002-08
NCT00328302 UNKNOWN
Diabetes, Type I
Karolinska University Hospital
 2000-09 PHASE4
NCT00356395 COMPLETED
Hypertension
Gachon University Gil Medical Center
 2003-08 PHASE4
NCT00192803 UNKNOWN
NIDDM
Rambam Health Care Campus
 PHASE4
NCT00430833 UNKNOWN
Hypertrophic Cardiomyopathy
Charles University, Czech Republic
 PHASE2
NCT00141583 TERMINATED
Hypertension
St George's, University of London
 2004-04
NCT00154037 COMPLETED
Healthy Subjects
Technische Universität Dresden
 2005-10
NCT00235287 UNKNOWN
Kidney Failure, Chronic; Cardiovascular Diseases
Herlev Hospital
 2005-09 PHASE4
NCT00288717 UNKNOWN
Hypertension
Saitama Medical University
 2006-02
NCT00108706 UNKNOWN
Cerebrovascular Accident; Acute Stroke
City Hospitals Sunderland NHS Foundation Trust
 2004-12 PHASE4
NCT00930995 WITHDRAWN
Hepatitis C
Kaiser Permanente
 PHASE2
NCT00242346 COMPLETED
Proteinuria
AstraZeneca
 2003-04 PHASE3
NCT00125463 UNKNOWN
Hypertension; Cardiovascular Diseases
The Japanese Society of Hypertension
 2001-09 PHASE3
NCT00564057 UNKNOWN
HIV Infections; Hypertension
Università degli Studi dell'Insubria
 2007-09 PHASE4

(data from https://clinicaltrials.gov, updated on 2026-06-17)

Check the Candesartan product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Candesartan selectively binds to and antagonizes the angiotensin II type 1 receptor, thereby blocking angiotensin II-mediated vasoconstriction, aldosterone secretion, and vascular smooth muscle proliferation. This cellular inhibition promotes systemic vasodilation and reduces systemic vascular resistance, providing the pharmacological basis for its clinical efficacy in managing hypertension, chronic heart failure, and dilated cardiomyopathy.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.